Cx Precision Medicine, Inc.

Cx Precision Medicine, Inc. CEO Danguole Altman is wrapping up a fascinating trip to Davos World Economic Forum where she congratulates the Davos Alzheimer's Collaborative for sponsoring The Brain House. Conversations at The House focused on the importance of brain health over a lifespan, not only to the individual but to a successful economy. Another highlight was the talk by Takeda CEO Christophe Weber at the Axios and Lightspeed Venture Partners' panel on the Future of AI and Healthcare. #Davos #alzheimers #future

Cx Precision Medicine, Inc. CEO Danguole Altman is at The Brain House, part of the annual Davos World Economic Forum, where George Vradenburg, Chairman of the Davos Alzheimer's Collaborative is speaking. The Brain House is hosted by the Davos Alzheimer's Collaborative, where the world’s top experts in neuroscience, healthcare, and innovation come together to accelerate breakthroughs in the fight against Alzheimer's disease. A series of events happening Jan. 20-24 will feature leading experts in health and innovation who are advancing global brain health. The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places. #TheBrainHouse #Davos2025 #alzheimers #leadership #innovation

Great to see this piece and congratulations to our Scientific Founder, Sid Obryant and team on creating this "unicorn" to ultimately help more people diagnose Alzheimer's Disease and find the care they need. #alzheimers #dementia https://lnkd.in/gz__dJAs

Cx Precision Medicine, Inc. CEO Danguole Altman reports from Boston: "So inspired seeing my Harvard 1981 classmate, HBS Professor Amy Edmondson, interview Sir Andrew Witty, CEO, UnitedHealth Group on the future of healthcare at the HBS Healthcare Alumni Association meeting. Discussing need for efficiency and individual empowerment paired with technology as powerful drivers of change in next decade and more. Fascinating discussion." Harvard Business School #healthcare #future

Thank you Fort Worth INC. for featuring us in your latest issue. We are proud to be part of the amazing #FortWorth and North Texas Biotech community. TechFW BioNTX Sid O’Bryant, Ph.D. University of North Texas Health Science Center College of Public Health Danguole Altman Darlene Boudreaux Carol Berry Heather Giles PhD, FBPharmacolS https://lnkd.in/gwhmxEsX

Thank You to StartUp Health for this excellent profile of Cx Precision Medicine, Inc. in the most recent issue of their Health Transformer Journal. CxPM is honored to be part of StartUp Health’s Alzheimer’s Moonshot Program which brings together innovative companies, research teams and stakeholders to accelerate progress in prevention, diagnosis and management of Alzheimer’s disease and related dementias. To learn more about CxPrecision Medicine visit our website: CxPrecisionM.com #dementia #alzheimers Danguole Altman Sid O’Bryant, Ph.D. https://lnkd.in/g9338FqA

Thanks to BioNTX for inviting Cx Precision Medicine, Inc. to participate in this week's 2024 iC³ Life Science & Healthcare Innovation Summit. Carol Berry, CxPM Chief Business Officer, made a company presentation before an attentive group of leaders from the dynamic North Texas bioscience and healthcare community. CxPM's NeuroFirst™ Memory test is the only blood-based test for primary care physicians use to rule out Alzheimer's Disease and related dementias, allowing doctors to triage which patients are unlikely to have dementia and should be evaluated and treated for other causes. CxPM's NeuroFirst™ Tests for AD are based on the extensive research and development led by Sid O’Bryant, Ph.D. at the University of North Texas Health Science Center College of Public Health. For more information visit: CxPrecisionM.Com #Dallas #Texas #alzheimers

Cx Precision Medicine, Inc. CEO Danguole Altman (right) with Phyllis Ferrell, Chief Impact Officer of StartUp Health's Alzheimers Moonshot Program, at the Lausanne XI Meeting sponsored by Davos Alzheimer's Collaborative and Us Against Alzheimers in Lausanne, Switzerland. Shown here on the terrace of the Olympic Museum at a reception hosted by the Global BHP BrainTrust. The Lausanne XI Meeting is a global gathering of leaders in government, pharma, advocacy groups, innovators and others, all focused on ending Alzheimer's Disease. #alzheimers #brainhealth Sid O’Bryant, Ph.D.

Excited to share the news that Cx Precision Medicine, Inc. has been accepted into StartUp Health's Alzheimer's Moonshot Program. This is a global initiative created to develop a collaborative innovation community alongside leading companies, research teams, and stakeholders with a mission to accelerate progress in prevention, diagnosis, and management of Alzheimer’s disease and related dementias. The Alzheimer’s Moonshot Program, established in January 2024, is a partnership between StartUp Health, the Alzheimer's Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates. The program’s goal is to bring together a diverse network of key players to drive innovation and collaboration for the Alzheimer’s community. “We are excited to be a part of the Alzheimer’s Moonshot Community to enable CxPM to foster many collaborations within the community and bring precision diagnostics to doctors and patients to improve the care of this devastating disease,” said Danguole Altman, CEO of CxPM, “Being selected to join the Program involved a rigorous evaluation of CxPM, our management team, research and innovation. We are honored to have been asked to join this powerful network of innovators” Over 55 million people worldwide are living with Alzheimer disease creating a substantial need for early detection of the disease. CxPM’s technology was developed at Dr. Sid O’Bryant, Ph.D.’s laboratory at The University of North Texas Health Science Center College of Public Health in Ft. Worth, Texas. Dr. O‘Bryant is one of the nation’s pioneers in using blood based biomarkers and predictive algorithms to develop better tools for primary care physicians to accurately diagnose and triage patients with potential signs and symptoms of Alzheimer’s disease and related dementias (ADRD). CxPM, a transformative diagnostic company, utilizing AI/machine learning and proteomics to accelerate the diagnostic pathway for patients with neurodegenerative disease. CxPM's NeuroFirst™ Memory test is the only blood-based test for primary care to rule out ADRD, allowing doctors to triage which patients are unlikely to have dementia and should be evaluated and treated for other causes. CxPM's NeuroFirst™ Memory test decreases unnecessary referrals to specialists and increases diagnostic accuracy.  The underlying technology was developed with extensive NIH funding and exclusively licensed from UNTHSC. Validations will be completed by year end and the test will launch selectively in 2025.  Read more in the full Press Release: https://lnkd.in/dFig6-wP Learn more about Cx Precision Medicine at: CxPrecisionM.com #alzmoonshot #alzheimers #ADRD

Thank you StartUp Health for inviting Cx Precision Medicine, Inc. to join the Alzheimer's Moonshot Community. We look forward to many collaborations and to bringing precision diagnostics to doctors and patients to improve the care of this devastating disease. #alzheimers #AlzMoonshot https://lnkd.in/dvZq8bqv